Lead Product(s) : QBKPN SSI
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : National Research Council of Canada Industrial Research Assistance Program
Deal Size : $6.6 million
Deal Type : Funding
Details : QBKPN SSI is designed to reprogram the functional competence of immune cells to fix the immune dysregulation that typically develops with aging, providing broad immune protection, not only against COVID-19.
Product Name : QBKPN SSI
Product Type : Vaccine
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : QBKPN SSI
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : National Research Council of Canada Industrial Research Assistance Program
Deal Size : $6.6 million
Deal Type : Funding
Lead Product(s) : Fenretinide
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAU-7b (oral fenretinide) is a novel candidate that acts on cell membrane lipids to modulate inflammation signaling and protein trafficking. Fenretinide was shown to correct the levels of certain membrane phospholipids and sphingolipids in multiple in vi...
Product Name : LAU-7b
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Fenretinide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease
Details : Company plans to start a Phase 2 trial in the first half of 2021 evaluating a novel rifaximin formulation for a potential sickle cell disease treatment.
Product Name : Xifaxan
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Rifaximin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable